Printer Friendly

NANOGEN SHIPS FIRST MOLECULAR BIOLOGY WORKSTATION TO AVENTIS.

Nanogen, Inc. (Nasdaq: NGEN), San Diego, Calif., has announced the first commercial sale of its NanoChip Molecular Biology Workstation. The NanoChip system was sold to Aventis Research & Technologies, an affiliate of Aventis (NYSE: AVE).

Mr. Birndorf, Nanogen's chairman, CEO and president, commented, "The shipment of our first commercial product is an exciting milestone for Nanogen. We are pleased to have launched what we hope is the next phase of Nanogen's growth. It is encouraging that Aventis, a company with significant experience with Nanogen and our technologies, asked to be our first customer."

Nanogen recently began marketing its NanoChip(TM) molecular biology workstation to scientists and genomics laboratories, setting new standards for SNP scoring or genotyping. In beta testing at third party sites and in demonstrations with customer samples at Nanogen, the NanoChip(TM) system has been shown to provide accuracy equal to or better than DNA sequencing and other methods for SNP confirmation. Whereas most hybridization, sequencing and primer extension technologies require high salt conditions and/or enzyme mediation, the NanoChip(TM) system uses electronically accelerated hybridization under very low salt conditions and no enzymes, avoiding many of the problems associated with DNA conformation and secondary structures. The NanoChip(TM) system allows the user to array and analyze DNA on its NanoChip(TM) cartridges in user selected formats in a single day with walk-away automation.

Nanogen initiated pre-commercialization activities for the NanoChip(TM) Molecular Biology Workstation during the first half of 2000. The instruments shipped to Aventis were manufactured by Nanogen and its previous instrument vendors. Technology transfer with Nanogen's instrument partner, Hitachi Instruments Group, was initiated in January, and initial receipt of product from Hitachi is expected during the third quarter. Hitachi manufactures a variety of instrumentation at their Naka works in Japan under Good Manufacturing Practices (GMP) guidelines and ISO 9000 including many analyzers for use in clinical diagnostics. In addition, Nanogen hired and trained the first members of its sales force and applications specialist team in April. The Company is supporting the sales and applications teams with the recent opening of the Nanogen Customer Applications Laboratory where prospective customers can submit samples to experience the accuracy, ease-of-use and flexibility of the NanoChip(TM) system.

Birndorf commented, "We had anticipated our first commercial sale would take place in the third quarter of 2000. We are pleased to have exceeded our expectation by completing our first sale in early June. We are very encouraged by the level of interest our sales force has encountered with prospective customers and by the positive feedback from customers who have used our Customer Applications Laboratory to compare our technology versus their current solutions. I continue to expect that our primary commercial activity ramp up will occur in the third quarter as Hitachi-manufactured instruments become available and customer reference sites are established."

Nanogen, Inc. integrates advanced microelectronics and molecular biology into a platform technology with potentially broad commercial applications in the fields of biomedical research, genomics, medical diagnostics, genetic testing and drug discovery. Nanogen's fully automated molecular biology workstation, which incorporates a proprietary semiconductor microchip, the NanoChip(TM), provides a flexible tool for the rapid identification and analysis of test samples containing charged molecules. Nanogen's technology allows the simultaneous analysis of multiple test sites, or multiplexing, from a single sample. The company has established corporate alliances in certain areas as part of its strategy to expand the applications and accelerate the commercialization of products derived from its technology.

Aventis is a world leader in life sciences. Focused on two core business areas -- pharmaceuticals and agriculture -- Aventis is dedicated to improving life through the discovery and development of innovative products in the fields of prescription drugs, vaccines, therapeutic proteins, crop production and protection, animal health and nutrition. Aventis global corporate headquarters are in Strasbourg, France.

For more information, call 858-410-4600.
COPYRIGHT 2000 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:NANOGEN SHIPS FIRST MOLECULAR BIOLOGY WORKSTATION TO AVENTIS.
Publication:Computer Workstations
Article Type:Product Announcement
Geographic Code:1USA
Date:Jul 1, 2000
Words:635
Previous Article:IBM INTEGRATES ENVISTA PKS INTO ITS ASIC DESIGN FLOW.
Next Article:COMPAQ TECHNOLOGY ENABLES COMPLETION OF HUMAN GENOME.
Topics:


Related Articles
Random Samples.
Random Samples.
NANOGEN SIGNS 10 NONOCHIP WORKSTATION AGREEMENTS.
Nanogen awarded United States patent on method for detecting nucleic acid hybridization by means of fluorescent energy transfer.
Nanogen issued patent for enhancing molecular biological reactions.
Nanogen issued patent for device that combines optical waveguides and molecular diagnostics.
Nanogen announces patent for fluorescent detection of nucleic acid targets.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters